Drugs / SR-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07581197 | Nov 2026 → Nov 2028 expected | type 1 diabetes mellitus | Seraxis | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06651515 | Apr 2025 → Mar 2027 | type 1 diabetes mellitus | Seraxis | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-10-15 | Seraxis | Regulatory Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes seraxis.com ↗
Seraxis Inc., a clinical stage regenerative medicine company, has received FDA’s allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02. |
| 2023-10-26 | Seraxis | Results Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. seraxis.com ↗
Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. |
| 2023-09-28 | Seraxis | Results Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD. seraxis.com ↗
In themouse model of STZ induced Type 1 Diabetes, organoid implantation resulted in glycemiccontrol 3-4 weeks post-implant. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR-02 | “SR-02 allogeneic pancreatic endocrine cell clusters” NCT07581197 ↗1“SR-02 Allogeneic pancreatic endocrine cell clusters” NCT06651515 ↗ |
| Modality | Cell therapy | “Allogeneic Pancreatic Endocrine Cell Clusters” NCT06651515 ↗ |
| Route | Other | “SR-02 administered to the omentum” NCT06651515 ↗ |